阿司匹林和他汀类药物被认为对胃癌（GC）具有潜在的化学预防作用，尽管之前的研究结果并不一致。因此，本研究旨在调查阿司匹林和他汀类药物的使用与胃癌之间的关联。对胃癌汇集项目内的七项病例对照研究（包括 3220 例病例和 9752 例对照）进行了汇总分析。在调整潜在混杂因素后，采用两阶段建模分析来估计阿司匹林和他汀类药物的使用与 GC 之间的关联。阿司匹林使用者与非使用者的 GC 的合并比值比 (OR) 为 0.72（95% 置信区间 [CI]，0.54） -0.95）。阿司匹林的保护作用在没有 GC 家族史的个体中似乎更强（OR，0.60；95% CI，0.37-0.95），尽管有和没有家族史的个体之间存在边缘异质性（p = .064）。 GC 的 OR 随着阿司匹林使用时间的增加而降低，持续时间≥15 年的 OR 为 0.41（95% CI，0.18-0.95）。观察到单独使用他汀类药物与 GC 风险呈非显着负相关（OR，0.79；95% CI，0.52-1.18）。这些发现表明，阿司匹林的使用，尤其是长期使用，与减少GC 的风险，而他汀类药物则没有观察到类似的关联，可能是因为使用频率低。© 2024 作者。 《癌症》由 Wiley periodicals LLC 代表美国癌症协会出版。

Aspirin and statins have been suggested to have potential chemopreventive effects against gastric cancer (GC), although the results of previous studies have been inconsistent. This study therefore aimed to investigate the association between the use of aspirin and statins and GC.A pooled analysis of seven case-control studies within the Stomach Cancer Pooling Project, including 3220 cases and 9752 controls, was conducted. Two-stage modeling analyses were used to estimate the association between aspirin and statin use and GC after adjusting for potential confounders.The pooled odds ratio (OR) of GC for aspirin users versus nonusers was 0.72 (95% confidence interval [CI], 0.54-0.95). The protective effect of aspirin appeared stronger in individuals without a GC family history (OR, 0.60; 95% CI, 0.37-0.95), albeit with borderline heterogeneity between those with and without a family history (p = .064). The OR of GC decreased with increasing duration of aspirin use, with an OR of 0.41 (95% CI, 0.18-0.95) for durations of ≥15 years. An inverse, nonsignificant association with the risk of GC was observed for the use of statins alone (OR, 0.79; 95% CI, 0.52-1.18).These findings suggest that aspirin use, particularly long-term use, is associated with a reduced risk of GC, whereas a similar association was not observed with statins, possibly because of the low frequency of use.© 2024 The Author(s). Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.